---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028535"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:22:53.007682+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avalo Q3 net income $3.2M on $14.5M license; cash $16.9M; AVTX-002 data H1 2023

## Summary
- Q3 net income of $3.2M vs $17.4M loss in 2021; net revenues $15M including $14.5M license revenue.
- Cash $16.9M at Sep 30 2022, down $37.7M from Dec 31 2021; operating expenses fell $23.6M YTD.
- Agreement to sell net economic rights to legacy out-licensed assets (AVTX-007, -501, -611) for $5M due Nov 2022.
- Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma enrollment to complete by end of 2022; topline data H1 2023.
- Pivotal LADDER trial of AVTX-803 in LAD II on track for data in H1 2023.

## SEC filing metadata
- accession: 0001628280-22-028535
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/0001628280-22-028535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/avtx-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028535
- JSON: https://secwatch.observer/filing/0001628280-22-028535.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028535.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/0001628280-22-028535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.